<document>

<filing_date>
2019-11-26
</filing_date>

<publication_date>
2020-03-19
</publication_date>

<priority_date>
2011-03-04
</priority_date>

<ipc_classes>
G01N33/574,G01N33/68
</ipc_classes>

<assignee>
IMMUNOVIA
</assignee>

<inventors>
BORREBAECK, CARL, ARNE, KRISTER
WINGREN, LARS, BERTIL, CHRISTER
</inventors>

<docdb_family_id>
43923218
</docdb_family_id>

<title>
METHOD, ARRAY AND USE FOR DETERMINING THE PRESENCE OF PANCREATIC CANCER
</title>

<abstract>
The present invention relates to a method for determining the presence of pancreatic cancer in an individual comprising or consisting of the steps of: (a) providing a sample to be tested from the individual, and (b) determining a biomarker signature of the test sample by measuring the expression in the test sample of one or more biomarkers selected from the group defined in Table III, wherein the expression in the test sample of one or more biomarkers selected from the group defined in Table III is indicative of the individual having pancreatic cancer. The invention also comprises arrays and kits of parts for use in the method of the invention.
</abstract>

<claims>
1. A method for determining the presence of pancreatic cancer in an individual comprising or consisting of the steps of: a) providing a sample to be tested from the individual; b) determining a biomarker signature of the test sample by measuring the expression in the test sample of one or more biomarkers selected from the group defined in Table III; wherein the expression in the test sample of one or more biomarkers selected from the group defined in Table III is indicative of the individual having pancreatic cancer; and wherein step (b) comprises or consists of measuring the expression of one or more of the biomarkers listed in Table IV(A) and/or Table IV(B).
2. The method according to claim 1 further comprising or consisting of the steps of: c) providing a control sample from an individual not afflicted with pancreatic cancer; d) determining a biomarker signature of the control sample by measuring the expression in the control sample of the one or more biomarkers measured in step (b); wherein the presence of pancreatic cancer is identified in the event that the expression in the test sample of the one or more biomarkers measured in step (b) is different from the expression in the control sample of the one or more biomarkers measured in step (d).
3. The method according to claim 1 or 2 further comprising or consisting of the steps of: e) providing a control sample from an individual afflicted with pancreatic cancer; f) determining a biomarker signature of the control sample by measuring the expression in the control sample of the one or more biomarkers measured in step (b); wherein the presence of pancreatic cancer is identified in the event that the expression in the test sample of the one or more biomarkers measured in step (b) corresponds to the expression in the control sample of the one or more biomarkers measured in step (f).
4. The method according to claim 1, 2 or 3, wherein step (b) comprises or consists of measuring the expression of one or more of the biomarkers listed in Table IV(A), for example, at least 2 of the biomarkers listed in Table IV(A).
5. The method according to any one of the preceding claims, wherein step (b) comprises or consists of measuring the expression of interleukin-7 (IL-7) and/or integrin alpha-10, for example, measuring the expression of interleukin-7, measuring the expression of integrin alpha-10, or measuring the expression of interleukin-7 and integrin alpha-10.
6. The method according to any one of the preceding claims, wherein step (b) comprises or consists of measuring the expression of each the biomarkers listed in Table IV(A).
7. The method according to any one of the preceding claims, wherein step (b) comprises or consists of measuring the expression of 1 or more of the biomarkers listed in Table IV(B), for example at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 of the biomarkers listed in Table IV(B).
8. The method according to any one of the preceding claims, wherein step (b) comprises or consists of measuring the expression of all of the biomarkers listed in Table IV(B).
9. The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the expression of 1 or more biomarkers from the biomarkers listed in Table IV(C), for example at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or 41 of the biomarkers listed in Table IV(C).
10. The method according to any one of the preceding claims, wherein step (b) comprises or consists of measuring the expression of all of the biomarkers listed in Table IV(C).
11. The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the expression in the test sample of all of the biomarkers defined in Table IV.
12. The method according to any one of the preceding claims, wherein the method is for differentiating between pancreatic cancer (PaC) and any other disease state or states.
13. The method according to claim 12, wherein step (b) comprises or consists of measuring the expression in the test sample of 1 or more biomarkers from the biomarkers listed in Table V(A), for example at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 of the biomarkers listed in Table V(A).
14. The method according to claim 12 or 13, wherein step (b) comprises or consists of measuring the expression in the test sample of 1 or more biomarkers from the biomarkers listed in Table V(B), for example at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 of the biomarkers listed in Table V(B).
15. The method according to claim 12, 13 or 14, wherein step (b) comprises or consists of measuring the expression in the test sample of 1 or more biomarkers from the biomarkers listed in Table V(C), for example at least 2, 3, 4 or 5 of the biomarkers listed in Table V(C).
16. The method according to any one of claims 12 to 15, wherein step (b) comprises or consists of measuring the expression in the test sample of 1 or more biomarkers from the biomarkers listed in Table V(D), for example at least 2 or 3 of the biomarkers listed in Table V(D).
17. The method according to any one of claims 12 to 16, wherein step (b) comprises or consists of measuring the expression in the test sample of 1 or more biomarkers from the biomarkers listed in Table V(F), for example at least 2, 3, 4, 5 or 6 of the biomarkers listed in Table V(F).
18. The method according to any one of claims 12 to 17, wherein step (b) comprises or consists of measuring the expression in the test sample of all of the biomarkers listed in Table V(A), Table V(B), Table V(C), Table V(D) and/or Table V(F).
19. The method according to any one of claims 12 to 18, wherein the other disease state or states is chronic pancreatitis (ChP), acute inflammatory pancreatitis (AIP) and/or normal, for example, the other disease state or states may be chronic pancreatitis alone; acute inflammatory pancreatitis alone; chronic pancreatitis and acute inflammatory pancreatitis; chronic pancreatitis and normal; acute inflammatory pancreatitis and normal; or, chronic pancreatitis, acute inflammatory pancreatitis and normal.
20. The method according to any one of claims 1 to 11, wherein the method is for differentiating between pancreatic cancer and chronic pancreatitis (ChP).
21. The method according to claim 20, wherein step (b) comprises or consists of measuring the expression in the test sample of 1 or more biomarkers from the biomarkers listed in Table V(A), for example at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 of the biomarkers listed in Table V(A).
22. The method according to claim 20 or 21, wherein step (b) comprises or consists of measuring the expression in the test sample of 1 or more biomarkers from the biomarkers listed in Table V(C), for example at least 2, 3, 4, or 5 of the biomarkers listed in Table V(C).
23. The method according to claim 20, 21, or 22, wherein step (b) comprises or consists of measuring the expression in the test sample of all of the biomarkers listed in Table V(A) and/or Table V(C).
24. The method according to any one of claims 1 to 11, wherein the method is for differentiating between pancreatic cancer and acute inflammatory pancreatitis (AIP).
25. The method according to claim 24, wherein step (b) comprises or consists of measuring the expression in the test sample of 1 or more biomarkers from the biomarkers listed in Table V(A), for example at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 of the biomarkers listed in Table V(A).
26. The method according to claim 24 or 25, wherein step (b) comprises or consists of measuring the expression in the test sample of 1 or more biomarkers from the biomarkers listed in Table V(B), for example at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 of the biomarkers listed in Table V(B).
27. The method according to claim 24, 25 or 26, wherein step (b) comprises or consists of measuring the expression in the test sample of 1 or more biomarkers from the biomarkers listed in Table V(C), for example at least 2, 3, 4 or 5 of the biomarkers listed in Table V(C).
28. The method according to any one of claims 24 to 27, wherein step (b) comprises or consists of measuring the expression in the test sample of 1 or more biomarkers from the biomarkers listed in Table V(E).
29. The method according to any one of claims 24 to 28, wherein step (b) comprises or consists of measuring the expression in the test sample of 1 or more biomarkers from the biomarkers listed in Table V(F), for example at least 2, 3, 4, 5 or 6 of the biomarkers listed in Table V(F).
30. The method according to any one of claims 24 to 29, wherein step (b) comprises or consists of measuring the expression in the test sample of 1 or more biomarkers from the biomarkers listed in Table V(H), for example at least 2 or 3 of the biomarkers listed in Table V(H).
31. The method according to any one of claims 24 to 30, wherein step (b) comprises or consists of or consists of measuring the expression in the test sample of all of the biomarkers listed in Table V(A), Table V(B), Table V(C), Table V(E), Table V(F) and/or Table IV(H).
32. The method according to any one of claims 1 to 11, wherein the method is for differentiating between pancreatic cancer and normal individuals (N).
33. The method according to claim 32, wherein step (b) comprises or consists of measuring the expression in the test sample of 1 or more biomarkers from the biomarkers listed in Table V(A), for example at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 of the biomarkers listed in Table V(A).
34. The method according to claim 32 or 33, wherein step (b) comprises or consists of measuring the expression in the test sample of 1 or more biomarkers from the biomarkers listed in Table V(B), for example at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 of the biomarkers listed in Table V(B).
35. The method according to claim 32, 33 or 34, wherein step (b) comprises or consists of measuring the expression in the test sample of 1 or more biomarkers from the biomarkers listed in Table V(D), for example at least 2 or 3 of the biomarkers listed in Table V(D).
36. The method according to any one of claims 32 to 35, wherein step (b) comprises or consists of measuring the expression in the test sample of 1 or more biomarkers from the biomarkers listed in Table V(E).
37. The method according to any one of claims 32 to 36, wherein step (b) comprises or consists of measuring the expression in the test sample of 1 or more biomarkers from the biomarkers listed in Table V(G), for example at least 2 or 3 of the biomarkers listed in Table V(G).
38. The method according to any one of claims 32 to 37, wherein step (b) comprises or consists of measuring the expression in the test sample of all of the biomarkers listed in Table V(A), Table V(B), Table V(D), Table V(E) and/or Table IV(G).
39. The method according to any one of claims 2 to 38, wherein the individual not afflicted with pancreatic cancer is not afflicted with pancreatic cancer (PaC), chronic pancreatitis (ChP) or acute inflammatory pancreatitis (AIP).
40. The method according to claim 39, wherein the individual not afflicted with pancreatic cancer is not afflicted with any pancreatic disease or condition.
41. The method according to claim 39 or 40, wherein the individual not afflicted with pancreatic cancer is not afflicted with any disease or condition.
42. The method according to claim 39, 40 or 41, wherein the individual not afflicted with pancreatic cancer is a healthy individual.
43. The method according to any one of claims 2 to 38, wherein the individual not afflicted with pancreatic cancer is afflicted with chronic pancreatitis.
44. The method according to any one of claims 2 to 38, wherein the individual not afflicted with pancreatic cancer is afflicted with acute inflammatory pancreatitis.
45. The method according to any one of the preceding claims wherein the pancreatic cancer is selected from the group consisting of adenocarcinoma, adenosquamous carcinoma, signet ring cell carcinoma, hepatoid carcinoma, colloid carcinoma, undifferentiated carcinoma, and undifferentiated carcinomas with osteoclast-like giant cells.
46. The method according to any one of the preceding claims wherein the pancreatic cancer is an adenocarcinoma.
47. The method according to any one of the preceding claims wherein step (b), (d) and/or step (f) is performed using a first binding agent capable of binding to the one or more biomarkers.
48. The method according to claim 47 wherein the first binding agent comprises or consists of an antibody or an antigen-binding fragment thereof.
49. The method according to claim 48 wherein the antibody or antigen-binding fragment thereof is a recombinant antibody or antigen-binding fragment thereof.
50. The method according to claim 48 or 49 wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of: scFv; Fab; a binding domain of an immunoglobulin molecule.
51. The method according to any one of claims 48 to 50 wherein the first binding agent is immobilised on a surface.
52. The method according to any one of claims 1 to 25 wherein the one or more biomarkers in the test sample are labelled with a detectable moiety.
53. The method according to any one of claims 2 to 25 wherein the one or more biomarkers in the control sample(s) are labelled with a detectable moiety.
54. The method according to claim 52 or 53 wherein the detectable moiety is selected from the group consisting of: a fluorescent moiety; a luminescent moiety; a chemiluminescent moiety; a radioactive moiety; an enzymatic moiety.
55. The method according to claim 52 or 53 wherein the detectable moiety is biotin.
56. The method according to any one of claims 47 to 55 wherein step (b), (d) and/or step (f) is performed using an assay comprising a second binding agent capable of binding to the one or more biomarkers, the second binding agent comprising a detectable moiety.
57. The method according to any one of claim 56 wherein the second binding agent comprises or consists of an antibody or an antigen-binding fragment thereof.
58. The method according to claim 57 wherein the antibody or antigen-binding fragment thereof is a recombinant antibody or antigen-binding fragment thereof.
59. The method according to claim 57 or 58 wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of: scFv; Fab; a binding domain of an immunoglobulin molecule.
60. The method according to any one of claims 56 to 59 wherein the detectable moiety is selected from the group consisting of: a fluorescent moiety; a luminescent moiety; a chemiluminescent moiety; a radioactive moiety; an enzymatic moiety.
61. The method according to claim 60 wherein the detectable moiety is fluorescent moiety (for example an Alexa Fluor dye, e.g. Alexa 647).
62. The method according to any one of the preceding claims wherein the method comprises or consists of an ELISA (Enzyme Linked Immunosorbent Assay).
63. The method according to any one of the preceding claims wherein step (b), (d) and/or step (f) is performed using an array.
64. The method according to claim 63 wherein the array is a bead-based array.
65. The method according to claim 63 wherein the array is a surface-based array.
66. The method according to any one of claims 63 to 65 wherein the array is selected from the group consisting of: macroarray; microarray; nanoarray.
67. The method according to any one of the preceding claims wherein the method comprises: (v) labelling biomarkers present in the sample with biotin; (vi) contacting the biotin-labelled proteins with an array comprising a plurality of scFv immobilised at discrete locations on its surface, the scFv having specificity for one or more of the proteins in Table III; (vii) contacting the immobilised scFv with a streptavidin conjugate comprising a fluorescent dye; and (viii) detecting the presence of the dye at discrete locations on the array surface wherein the expression of the dye on the array surface is indicative of the expression of a biomarker from Table III in the sample.
68. The method according to any one of claims wherein, step (b), (d) and/or (f) comprises measuring the expression of a nucleic acid molecule encoding the one or more biomarkers.
69. The method according to claim 68, wherein the nucleic acid molecule is a cDNA molecule or an mRNA molecule.
70. The method according to claim 68, wherein the nucleic acid molecule is an mRNA molecule.
71. The method according to claim 68, 69 or 70, wherein measuring the expression of the one or more biomarker(s) in step (b), (d) and/or (f) is performed using a method selected from the group consisting of Southern hybridisation, Northern hybridisation, polymerase chain reaction (PCR), reverse transcriptase PCR (RT-PCR), quantitative real-time PCR (qRT-PCR), nanoarray, microarray, macroarray, autoradiography and in situ hybridisation.
72. The method according to any one of claims 68-71, wherein measuring the expression of the one or more biomarker(s) in step (b) is determined using a DNA microarray.
73. The method according to any one of claims 68 to 72, wherein measuring the expression of the one or more biomarker(s) in step (b), (d) and/or (f) is performed using one or more binding moieties, each individually capable of binding selectively to a nucleic acid molecule encoding one of the biomarkers identified in Table III.
74. The method according to claim 73, wherein the one or more binding moieties each comprise or consist of a nucleic acid molecule.
75. The method according to claim 74 wherein, the one or more binding moieties each comprise or consist of DNA, RNA, PNA, LNA, GNA, TNA or PMO.
76. The method according to claim 74 or 75, wherein the one or more binding moieties each comprise or consist of DNA.
77. The method according to any one of claims 74-76 wherein the one or more binding moieties are 5 to 100 nucleotides in length.
78. The method according to any one of claims 74-76 wherein the one or more nucleic acid molecules are 15 to 35 nucleotides in length.
79. The method according to any one of claims 74-78 wherein the binding moiety comprises a detectable moiety.
80. The method according to claim 79 wherein the detectable moiety is selected from the group consisting of: a fluorescent moiety; a luminescent moiety; a chemiluminescent moiety; a radioactive moiety (for example, a radioactive atom); or an enzymatic moiety.
81. The method according to claim 80 wherein the detectable moiety comprises or consists of a radioactive atom.
82. The method according to claim 81 wherein the radioactive atom is selected from the group consisting of technetium-99m, iodine-123, iodine-125, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, phosphorus-32, sulphur-35, deuterium, tritium, rhenium-186, rhenium-188 and yttrium-90.
83. The method according to claim 80 wherein the detectable moiety of the binding moiety is a fluorescent moiety.
84. The method according to any one of the preceding claims wherein, the sample provided in step (b), (d) and/or (f) is selected from the group consisting of unfractionated blood, plasma, serum, tissue fluid, pancreatic tissue, pancreatic juice, bile and urine.
85. The method according to claim 84, wherein the sample provided in step (b), (d) and/or (f) is selected from the group consisting of unfractionated blood, plasma and serum.
86. The method according to claim 84 or 85, wherein the sample provided in step (b), (d) and/or (f) is plasma.
87. An array for determining the presence of pancreatic cancer in an individual comprising one or more binding agent as defined in any one of claims 47 to 61.
88. An array according to claim 87 wherein the one or more binding agents is capable of binding to all of the proteins defined in Table III.
89. Use of one or more biomarkers selected from the group defined in Table III as a diagnostic marker for determining the presence of pancreatic cancer in an individual.
90. The use according to claim 89 wherein all of the proteins defined in Table III are used as a diagnostic marker for determining the presence of pancreatic cancer in an individual.
91. A kit for determining the presence of pancreatic cancer comprising: C) one or more first binding agent as defined in any one of claims 47 to 55 or an array according to claims 63 to 66 or claim 87 or 88; D) instructions for performing the method as defined in any one of claims 1 to 67 or 68 to 86.
92. A kit according to claim 31 further comprising a second binding agent as defined in any one of claims 56 to 61.
93. A method or use for determining the presence of pancreatic cancer in an individual substantially as described herein.
94. An array or kit for determining the presence of pancreatic cancer in an individual substantially as described herein.
</claims>
</document>
